BioPhorum response to the FDA discussion paper on Artificial Intelligence in Drug Manufacturing. It also also presents a global picture of the current state of the biomanufacturing industry on the implementation of AI. It can be used by subject matter experts, business leaders, and key opinion makers to assess their current AI maturity level compared to others and potentially identify future areas of collaboration.

read more